Skip to Content

Posts tagged with "Business and Markets"

  • Business and Markets

    Perhaps Not Quite Technically Legal, Come to Think of It

    Now, wait – you’re telling me that just because you’re a doctor involved in the clinical trial of a small company’s main drug, and you’ve found out that the trial has been halted by the FDA. . .you’re saying that you can’t actually unload all your stock on that information before the public announcement? Wh… Read More
  • Business and Markets

    AstraZeneca Says No Again

    Now what? Pfizer has upped its offer for AstraZeneca yet again, and up to the figure that they seem to have calculated would bring them to the negotiating table. But AZ has told them to buzz off yet again, sending their own shares down hard. That’s because Pfizer also stated that they would not launch… Read More
  • Business and Markets

    China Raises the Stakes in the GSK Scandal

    GSK’s troubles in China have just gotten even more serious. The government has formally charged Mark Reilly, former head of the company’s operations in China, of organizing and participating in a bribery scheme. This seems to have been a stronger step than people were expecting – we’ll see what happens. Reilly’s wherea… Read More
  • Business and Markets

    Pfizer’s Shareholders and AstraZeneca’s

    The Financial Times is out with an editorial denouncing Pfizer’s attempted takeover of AstraZeneca. It’s definitely worth a read for the case it makes. What’s a drug company supposed to be doing, anyway? But (the effect on British research) is not the only big question requiring discussion. Another is the extent to which the board… Read More
  • Business and Markets

    Pfizer-AZ: Politics and Press Releases

    This saga is going to be running for a while; we might as well all resign ourselves to it. The latest seems to be that the British government is getting more visibly into the act. The Business Secretary, Vince Cable, has said that he’s not going to let Pfizer use the UK as a tax… Read More
  • Business and Markets

    The Lessons of Intercept and NASH

    Over at LifeSciVC, Tom Hughes has a post about Intercept Pharmaceuticals and their wild ride with an FXR ligand for non-alcoholic steatohepatitis (NASH). Anyone who owned ICPT will recall that period vividly, since the positive news from the clinical trial sent the company’s stock from an already-not-cheap $72/share to a where’s-the-oxy… Read More
  • Business and Markets

    AstraZeneca: Don’t Buy Us

    After Pfizer’s less-than-wonderful earnings report yesterday, AstraZeneca is out today painting a picture of how great things will be if they don’t get swallowed by them. John Carroll at FierceBiotech has the details, but I especially enjoyed his pithy comment on Twitter: “AZN made more promises today than I will ever see broken a… Read More
  • Business and Markets

    Fast Money, But What Direction Is It Going?

    If you’re inclined to get your financial info from fast-talking analysts on cable news channels, you might want to give this blog post a read. The author points out several egregious mistakes that CNBC’s “Fast Money” has made with biotech/pharma stocks by having traders giving out advice and forecasts despite apparently know… Read More
  • Business and Markets

    Pfizer/AstraZeneca: Asymmetric Cuts Look Likely

    So Pfizer is out today with some pretty bad financials, which are doubtless one reason for their determination to Go Out and Buy Somebody, whether they’re an R&D powerhouse or not. They’ve also been reassuring the British government that they’ll go ahead with the Cambridge research construction that AstraZeneca has begun, and… Read More
  • Business and Markets

    Some People at Pfizer Whose Fault This Isn’t

    It’s worth keeping in mind, as the Pfizer/AZ story develops, that there are some people that don’t get mentioned who aren’t enjoying this, either: the scientists in Pfizer’s labs. As I’ve mentioned, I know folks there, and I know that there are (still) an awful lot of good scientists working there. And they, of course… Read More
...293031...